Citigroup
BLTE

Citigroup’s Belite Bio BLTE Stock Holding History

Citigroup’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.24K Buy
47
+46
+4,600% +$7.05K ﹤0.01% 5276
2026
Q1 		$159 Sell
1
-2,136
-100% -$359K ﹤0.01% 5588
2025
Q4 		$342K Sell
2,137
-1,873
-47% -$222K ﹤0.01% 3751
2025
Q3 		$297K Buy
+4,010
New +$263K ﹤0.01% 3818
2025
Q2 		– Sell
-3
Closed -$199 – 5658
2025
Q1 		$199 Buy
+3
New +$181 ﹤0.01% 5414

Other funds holding BLTE

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HNWAG
High Net Worth Advisory Group Naples, Florida $471M AUM 22.07% 1-Year Est. Return
DACS
Dymon Asia Capital (Singapore) Singapore $2.39B AUM 150.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EFMH
E Fund Management (HK) Central, Hong Kong $302M AUM 64.42% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
WPA
West Paces Advisors Atlanta, Georgia $596M AUM 22.29% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Citigroup's BLTE Position: Q2 2026 in Review

Citigroup increased its Belite Bio (BLTE) stake by 4,600% in Q2 2026, buying an estimated $7.05K and bringing the position to 47 shares worth $7.24K. The position accounts for ﹤0.01% of the portfolio, ranked #5276.

Citigroup first reported a position in BLTE in Q1 2025 and has held it in 5 quarters since. The position peaked at $342K in Q4 2025. 12 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Citigroup held 47 shares of Belite Bio worth $7.24K as of Q2 2026.
  • Citigroup bought 46 Belite Bio shares in Q2 2026, an estimated $7.05K.
  • Belite Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5276 holding.
  • Citigroup first reported a position in Belite Bio in Q1 2025 and has held it in 5 quarters since.
  • Citigroup's Belite Bio position peaked at $342K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.